Columbia University

Regeneron's investigational gene therapy DB-OTO demonstrated clinically meaningful hearing improvements in 11 of 12 children with profound genetic hearing loss due to OTOF gene variants in the pivotal CHORD trial.

Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.

A comprehensive analysis of 19 clinical trials involving 6,506 patients found tramadol provides only minimal pain relief that falls below clinically meaningful thresholds for chronic pain management.

Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.

LinusBio published research in The Lancet's eBioMedicine demonstrating a novel hair-based biomarker for ALS detection using copper-related elemental patterns.

Columbia University scientists have developed an experimental mRNA-based universal antiviral therapy that provides short-term protection against multiple viruses including influenza and COVID-19.

The phase 3 ARCHER trial (NRG-GU015) is now enrolling 486 patients to compare ultra-hypofractionated stereotactic body radiation therapy (5 treatments) versus standard hypofractionated radiotherapy (20 treatments) for muscle invasive bladder cancer.

Gameto completed a $44 million Series C funding round led by Overwater Ventures, bringing total capital raised to $127 million for its stem cell-derived reproductive health therapies.

The FDA has issued a warning letter to Whoop alleging the company is marketing its Blood Pressure Insights feature without proper medical device approvals.

BioLineRx's CheMo4METPANC Phase 2 pilot study demonstrated a 64% overall response rate and 91% disease control rate in first-line pancreatic cancer patients treated with motixafortide combination therapy.